Terms: = Endocrine gland cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Prognosis
63 results:
1. Expression and clinical value of cxcr4 in high grade gastroenteropancreatic neuroendocrine neoplasms.
Pang C; Li Y; Shi M; Fan Z; Gao X; Meng Y; Liu S; Gao C; Su P; Wang X; Zhan H
Front Endocrinol (Lausanne); 2024; 15():1281622. PubMed ID: 38524630
[TBL] [Abstract] [Full Text] [Related]
2. Exploring Theranostic Avenues in Adrenocortical Carcinoma Using Chemokine Receptor and Prostate-Specific Membrane Antigen-Directed PET/CT.
Hahner S; Higuchi T; Serfling SE; Samnick S; Fuss CT; Heinze B; Buck AK; Schirbel A; Fassnacht M; Werner RA
Clin Nucl Med; 2024 Apr; 49(4):369-370. PubMed ID: 38350087
[TBL] [Abstract] [Full Text] [Related]
3. Exhausted Tumor-infiltrating CD39+CD103+ CD8+ T Cells Unveil Potential for Increased Survival in Human Pancreatic cancer.
Gorchs L; Fernández-Moro C; Asplund E; Oosthoek M; Solders M; Ghorbani P; Sparrelid E; Rangelova E; Löhr MJ; Kaipe H
Cancer Res Commun; 2024 Feb; 4(2):460-474. PubMed ID: 38335302
[TBL] [Abstract] [Full Text] [Related]
4. Tissue Expression and Prognostic Role of CXCL12 and cxcr4 in High-grade Serous Ovarian Carcinoma.
Lim H; Kim SI; Kim EN; Lee M; Lee C; Kim JW; Chung HH
Anticancer Res; 2023 Jul; 43(7):3331-3340. PubMed ID: 37351997
[TBL] [Abstract] [Full Text] [Related]
5. Increased SPRY1 expression activates NF-κB signaling and promotes pancreatic cancer progression by recruiting neutrophils and macrophages through CXCL12-cxcr4 axis.
Shi T; Li X; Zheng J; Duan Z; Ooi YY; Gao Y; Wang Q; Yang J; Wang L; Yao L
Cell Oncol (Dordr); 2023 Aug; 46(4):969-985. PubMed ID: 37014552
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
[TBL] [Abstract] [Full Text] [Related]
7. cxcr4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic cancer: CXCL12 Predicts Survival of Radically Resected Patients.
D'Alterio C; Giardino A; Scognamiglio G; Butturini G; Portella L; Guardascione G; Frigerio I; Montella M; Gobbo S; Martignoni G; Napolitano V; De Vita F; Tatangelo F; Franco R; Scala S
Cells; 2022 Oct; 11(21):. PubMed ID: 36359736
[TBL] [Abstract] [Full Text] [Related]
8. Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates cxcr4 mRNA Expression Levels to Potential Clinical Targets.
Kocher F; Puccini A; Untergasser G; Martowicz A; Zimmer K; Pircher A; Baca Y; Xiu J; Haybaeck J; Tymoszuk P; Goldberg RM; Petrillo A; Shields AF; Salem ME; Marshall JL; Hall M; Korn WM; Nabhan C; Battaglin F; Lenz HJ; Lou E; Choo SP; Toh CK; Gasteiger S; Pichler R; Wolf D; Seeber A
Clin Cancer Res; 2022 Nov; 28(22):4957-4967. PubMed ID: 36112544
[TBL] [Abstract] [Full Text] [Related]
9. cxcr4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma.
Zi D; Li Q; Xu CX; Zhou ZW; Song GB; Hu CB; Wen F; Yang HL; Nie L; Zhao X; Tan J; Zhou SF; He ZX
Aging (Albany NY); 2022 Jun; 14(11):4673-4698. PubMed ID: 35681259
[TBL] [Abstract] [Full Text] [Related]
10. Effect of bevacizumab combined with chemotherapy on SDF-1 and cxcr4 in epithelial ovarian cancer and its prognosis.
Ma C
World J Surg Oncol; 2022 May; 20(1):154. PubMed ID: 35545781
[TBL] [Abstract] [Full Text] [Related]
11. High ratio of pcxcr4/cxcr4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy.
Walther F; Berther JL; Lalos A; Ramser M; Eichelberger S; Mechera R; Soysal S; Muenst S; Posabella A; Güth U; Stadlmann S; Terracciano L; Droeser RA; Zeindler J; Singer G
BMC Cancer; 2022 Apr; 22(1):376. PubMed ID: 35397601
[TBL] [Abstract] [Full Text] [Related]
12. cxcr4 expression in tumor associated cells in blood is prognostic for progression and survival in pancreatic cancer.
Gardner KP; Tsai S; Aldakkak M; Gironda S; Adams DL
PLoS One; 2022; 17(3):e0264763. PubMed ID: 35259193
[TBL] [Abstract] [Full Text] [Related]
13. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic cancer: The COMBAT/KEYNOTE-202 Trial.
Bockorny B; Macarulla T; Semenisty V; Borazanci E; Feliu J; Ponz-Sarvise M; Abad DG; Oberstein P; Alistar A; Muñoz A; Geva R; Guillén-Ponce C; Fernandez MS; Peled A; Chaney M; Gliko-Kabir I; Shemesh-Darvish L; Ickowicz D; Sorani E; Kadosh S; Vainstein-Haras A; Hidalgo M
Clin Cancer Res; 2021 Sep; 27(18):5020-5027. PubMed ID: 34253578
[TBL] [Abstract] [Full Text] [Related]
14. Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far.
Wong W; Alouani E; Wei A; Ryu YK; Chabot JA; Manji GA
Semin Oncol; 2021 Feb; 48(1):57-68. PubMed ID: 33965249
[TBL] [Abstract] [Full Text] [Related]
15. circPVT1 regulates medullary thyroid cancer growth and metastasis by targeting miR-455-5p to activate CXCL12/cxcr4 signaling.
Zheng X; Rui S; Wang XF; Zou XH; Gong YP; Li ZH
J Exp Clin Cancer Res; 2021 May; 40(1):157. PubMed ID: 33962657
[TBL] [Abstract] [Full Text] [Related]
16. Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma.
Ollikainen RK; Kotkaranta PH; Kemppainen J; Teppo HR; Kuitunen H; Pirinen R; Turpeenniemi-Hujanen T; Kuittinen O; Kuusisto MEL
Leuk Lymphoma; 2021 Sep; 62(9):2151-2160. PubMed ID: 33856274
[TBL] [Abstract] [Full Text] [Related]
17. Determination of Potential Therapeutic Targets and Prognostic Markers of Ovarian cancer by Bioinformatics Analysis.
Zhang J; Huang S; Quan L; Meng Q; Wang H; Wang J; Chen J
Biomed Res Int; 2021; 2021():8883800. PubMed ID: 33829065
[TBL] [Abstract] [Full Text] [Related]
18. Development of
Trujillo-Nolasco M; Cruz-Nova P; Ferro-Flores G; Gibbens-Bandala B; Morales-Avila E; Aranda-Lara L; Vargas M; Ocampo-García B
J Biomed Nanotechnol; 2021 Feb; 17(2):263-278. PubMed ID: 33785097
[TBL] [Abstract] [Full Text] [Related]
19. Construction autophagy-related prognostic risk signature to facilitate survival prediction, individual treatment and biomarker excavation of epithelial ovarian cancer patients.
Fei H; Chen S; Xu C
J Ovarian Res; 2021 Mar; 14(1):41. PubMed ID: 33676525
[TBL] [Abstract] [Full Text] [Related]
20. Clinical association of cxcr4 in primary tumor of papillary thyroid cancer and response to iodine-131 treatment.
Sirakriengkrai K; Tepmongkol S; Keelawat S; Techavijit U
Nucl Med Commun; 2021 Apr; 42(4):396-401. PubMed ID: 33306632
[TBL] [Abstract] [Full Text] [Related]
[Next]